![]() |
Recombinant Factor IX (Alprolix) Brings Hope for Hemoph...
December 1, 2014 - Featured , In the News / Politics By: Benedette Cuffari, BS Toxicology Candidate c/o 2015 – Hemophilia B is an inherited bleeding disorder that is caused by a substantially reduced or complete lack of blood clotting factor IX. Therefore, people suffering from hemophilia B experience bleeding episodes that cause pain, irreversible joint damage, and life threatening hemorrhages. Approximately 28,000 people are currently… |
![]() |
Anticoagulation in Pregnant Women: Which Medications ar...
October 1, 2014 - Clinical , Featured By: Diana Gritsenko, PharmD Candidate 2015 – Multiple complications can arise during pregnancy. While venous thromboembolism (VTE) has a prevalence rate of just 0.06% it is one of the leading causes of maternal mortality. It is recommended that at-risk pregnant women receive anticoagulation therapy for a minimum of 3 months and VTE prophylaxis for the… |
![]() |
Drug Shortages: Effects & Costs in the United Stat...
August 1, 2014 - Featured , Professional Advice / Opinions By: Valentina DiGangi,PharmD Candidate c/o 2017, Brandon Hu, PharmD Candidate c/o 2018, Sang Hyo Kim, Staff Editor, Samantha Lau, PharmD Candidate c/o 2018, and Seowoo Yoon, PharmD Candidate c/o 2018 – What does a clinician do when there is limited access to a particular drug, such as morphine? Should they treat a patient who is… |
![]() |
Tailored Tablets...
August 1, 2014 - Featured , In the News / Politics By: Azia Tariq, Staff Editor – Truly personalized medication is the goal of researchers in the pharmaceutical and biotechnological industries. For example, when a patient requires a precise dose that is not manufactured as a tablet, the tablet will be broken up in order to deliver the dose as close as possible. Not only is… |
![]() |
The Use of Topical Opioid Treatment for Pressure Ulcer ...
May 1, 2014 - Clinical , Featured By: Katharine Cimmino, Editor-in-Chief – Pressure ulcers can be a painful condition decreasing the quality of life of patients and prolonging hospital stays.1 About 10% of hospital inpatients and 26% of hospice admissions have pressure sores.2 Pressure ulcers are injuries that occur when pressure is applied for prolonged periods of time over bony prominences.1 There… |
![]() |
Riociguat (Adempas®) New Drug for Pulmonary Hypertens...
April 1, 2014 - Clinical , Featured By: Hayeon Na, Co-Copy Editor [Content-Focused] – On October 8th of 2013, Bayer’s new drug riociguat (Adempas®) was approved for the treatment of patients whose pulmonary hypertension (PH) belongs in WHO groups 1 and 4.1 Riociguat (Adempas®) is a soluble guanylate cyclase (sGC) stimulator, and currently the only one of its kind on the market.… |
![]() |
The Surgeon General’s 2014 Report on Smoking...
April 1, 2014 - Featured , In the News / Politics By: Ada Seldin, Staff Editor – Since the first release of the Surgeon General’s Report on smoking 50 years ago, it has become clear that smoking results in premature death and a myriad of diseases, affecting almost every organ system. Public health initiatives to increase awareness, prevent initiation, and promote smoking cessation have been marginally… |
![]() |
Long Term PPI Use Heightens Concern of Associated Healt...
February 1, 2014 - Clinical , Featured By: Tamara Yunusova, Senior Staff Editor – Proton Pump Inhibitors (PPIs) are acid-reducing agents that have multiple uses in the treatment and prophylaxis of conditions such as peptic ulcer diseases, H. Pylori infection, Zollinger-Ellison syndrome, GERD, and NSAID gastroduodenal ulcers. Their versatility in treating a wide range of conditions, unparalleled efficacy over their Histamine-2-receptor antagonist… |
![]() |
New Alternative First Line Therapy for EGFR NSCLC...
January 1, 2014 - In the News / Politics By: Jenny Park, PharmD Candidate c/o 2015 – On July 12, 2013, the FDA approved afatinib (GilotrifTM) as a new first-line treatment for patients with late-stage non-small cell lung cancer (NSCLC), a type of carcinoma where specific types of epidermal growth factor receptor (EGFR) gene mutations are expressed.1 The drug afatinib irreversibly blocks EGFR, also… |
![]() |
New Hepatitis C Drug Receives FDA Approval...
January 1, 2014 - Clinical , Featured By: Ada Seldin, Staff Editor – On November 22, 2013, simeprevir (Olysio®), a new agent to treat chronic hepatitis C, received approval under the FDA’s priority review program. Simeprevir is an NS3/4A protease inhibitor that blocks the replication of the hepatitis C virus. Two other drugs from the same class, boceprevir and telaprevir, which were… |
![]() |
Direct Association of HIV and Early Kidney Damage in Wo...
January 1, 2014 - Featured , In the News / Politics By: Elizabeth Kopec, PharmD Candidate c/o 2014, South University School of Pharmacy at Columbia, SC – Human immunodeficiency virus (HIV) is a global pandemic, with approximately 35.3 million people infected in 2012. The United States currently has 1.3 million people living with HIV, with 20,000 deaths occurring every year due to acquired immune deficiency syndrome… |
![]() |
Ponatinib Taken Off the Market...
December 1, 2013 - In the News / Politics By: Sherine Jaison, PharmD Candidate c/o 2015 – The leukemia chemotherapy drug ponatinib (Iclusig) has just been taken off the market. The drug was under investigation by the Food and Drug Administration (FDA) following several reports of serious and life threatening blood clots and narrowing of the blood vessels.1 Ponatinib is a BCR-ABL tyrosine kinase… |
![]() |
Advancements Towards a Malaria Vaccine...
November 1, 2013 - In the News / Politics By: Sang Hyo Kim, Staff Editor – A new experimental vaccine, PfsPZ, offers great promise as a cure for malaria. PfsPZ demonstrated 100% success in protecting subjects from this mosquito-borne tropical disease, which affects about 200 million people and causes 660,000 death annually.1,2 Historically, it has been known that sustained immunity for malaria could be… |
![]() |
Ceftriaxone Induced Hemolytic Anemia...
November 1, 2013 - Clinical , Featured By: Samad Tirmizi, PharmD Candidate c/o 2014 – Hemolytic anemia (HA) is a type of anemia that occurs due to the breakdown of red blood cells. It is classified as intrinsic and extrinsic according to causative factors. Medication induced hemolytic anemia is an example of extrinsic, while genetic predisposition is an intrinsic factor. Drug induced… |
![]() |
After 15 Years, First New Recombinant Coagulation Facto...
October 1, 2013 - Clinical By: Tamara Yunusova, Senior Staff Editor – After a lengthy fifteen-year hiatus in recombinant drug approvals, FDA-approved Recombinant Coagulation Factor IX (Rixubis) has mounted to the forefront of Hemophilia B drug therapy. The recombinant coagulation factor gained orphan drug approval on June 26, 2013 for routine prophylaxis, control of bleeding episodes, and perioperative management in… |
![]() |
Nattokinase use in DVT prophylaxis...
October 1, 2013 - Clinical Samad Tirmizi, Pharm. D. Candidate c/o 2014 – Deep vein thrombosis (DVT) is a clot formation that occurs within deep veins, generally in the legs. This can cause swelling and pain due to the engorged vessels, and can eventually result in further complications such as a pulmonary embolism. Patients at high risk for DVT are… |
![]() |
Children, Codeine, and Cytochrome P-450...
September 1, 2013 - Clinical , Featured By Davidta Brown, Staff Editor – For post-operative pain treatment, few drugs are as trustworthy, as tried-and-true, as codeine. Prescriptive confidence in the analgesic has promoted its use in children recovering from uncomplicated surgeries, but the spate of injuries and deaths of young children who had been given codeine after undergoing adenotonsillectomies has provoked a… |
![]() |
A Close Concurrence on Certolizumab (Cimzia®)...
September 1, 2013 - Clinical , Featured By: Sang Hyo Kim, Staff Editor – This year, on July 23rd, FDA advisers voted 7 to 6, with one abstention, in favor of approving the drug certolizumab (Cimzia®) for the indication of axial spondyloarthritis (axSpA). axSpA is a chronic imflammatory condition that includes ankylosing spondylitis (AS) and non-radiographic axial spndyloarthristis (nr-axSpA).1,2 axSpA, AS and… |
![]() |
Comparison of the New Oral Antithrombotics and Warfarin...
August 1, 2013 - Clinical , Featured By Omar Khalid Pharm.D. Candidate c/o 2014 – The outpour of a multitude of new oral anticoagulants in recent years has health care professionals questioning whether they should switch the patients over, and what new agents should be used. With the recent addition of dabigatran (Pradaxa®) in October 2010, rivaroxaban (Xarelto®) in November 2011, and… |
![]() |
Two New Agents for the Treatment of Obesity...
August 1, 2013 - Clinical , Featured By: Nathan Trustman, PharmD Candidate c/o 2013, AMSCOP at LIU – Obesity is defined as having a body mass index (BMI) of 30 kg/m2 or greater. It is thought to be the result of an imbalance between energy intake and energy expenditure, possibly due to a number of genetic and environmental factors.1 It is estimated… |
![]() |
Interview with Dr. Omudhome Ogbru, Founder of RxEconsul...
June 1, 2013 - Featured , Professional Advice / Opinions By: Steve Soman, PharmD Candidate c/o 2013 – Q: I see that you got your PharmD at the University of the Pacific. Looking back, what made you choose pharmacy and how has this changed over the years of your practice (if it has)? A: I became a pharmacist because I like to care for others… |
![]() |
Flu Season 2012-2013: Rising Opportunities for Pharmaci...
April 1, 2013 - Clinical By: Fawad Piracha, Pharm. D Candidate c/o 2016 – The 2012-2013 influenza season has developed into one of the greatest nationwide flu outbreaksof the decade.1 Amid this crisis, many flocked to healthcare providers with flu-like symptoms, while others scoured doctors’ offices, clinics, and pharmacies for the vaccine. With the flu claiming many lives throughout the… |
![]() |
FDA Approves Apixaban For Nonvalvular Atrial Fibrillati...
January 1, 2013 - Clinical , Featured , In the News / Politics By: Alexandra Alleva, PharmD candidate c/o 2013 – As of December 28th, Bristol-Myers Squibb and Pfizer’s brand name oral anticoagulant, Eliquis® (apixaban), attained FDA approval.1 This occurred one month after its approval in Europe and Canada, following longer than expected waits in the US due to further investigation requests by the FDA.2 The much-anticipated anticoagulant is… |
![]() |
New Drug Review: Tofacitinib (Xeljanz®)...
November 1, 2012 - Clinical By: Jessica Lee, PharmD Candidate c/o 2013 – Rheumatoid arthritis (RA) is an autoimmune disease in which the immune system attacks healthy tissue, causing inflammation of the joints and potential harm to other organs.1 It affects 0.5-1% of the adult population and is more prevalent in the seventh decade of life.1 These patients tend to… |
![]() |
Antiplatelet Use Following Acute Coronary Syndromes...
September 1, 2012 - Clinical , Featured By: Addolorata Ciccone, Co-Copy Editor – Acute Coronary Syndromes Acute coronary syndrome (ACS) is a myocardial ischemia caused by obstruction of coronary arteries. ACS is stratified into three types, based on electrocardiogram (EKG) changes and the presence of cardiac biomarkers (e.g. troponin, creatinine phosphokinase, and myoglobin). To guide treatment plans, it is important to identify… |
![]() |
Nutrition Support Pharmacy Practice...
August 1, 2012 - Professional Advice / Opinions By: James W. Schurr, PharmD Candidate c/o 2014 – Nutrition Support Pharmacy is a specialized practice pertaining to the needs of patients receiving Parenteral (PN) or Enteral Nutrition (EN). Nutrition Support Pharmacists (NSPs) are integral members of the nutritional support team and bring valuable skills and knowledge to the clinical practice setting. The Board of… |
![]() |
The Role of N-Acetylcysteine in Contrast Induced Nephro...
August 1, 2012 - Clinical By: Neal Shah, Co-Editor-In-Chief – Contrast dyes enhance imaging for computer tomography (CT), magnetic resonance (MR), and X-rays.1 Dyes usually consist of barium, iodine, or gadolinium, depending on the procedure.2 CT and X-ray scans often use iodine for systemic imaging and barium sulfate for GI imaging, whereas MR imaging primarily uses gadolinium.2 Gadolinium and iodine… |
![]() |
Understanding Diabetic Ketoacidosis...
July 1, 2012 - Clinical , Featured By: Mohamed Dungersi, Associate Student Editor – What is diabetic ketoacidosis (DKA)? Diabetic ketoacidosis (DKA) is an acute complication of uncontrolled diabetes or hyperglycemia. It is usually observed in cases of extreme hyperglycemia (usually in excess of 500 mg/dl, though it can occur over 250 mg/dl).1,2 It is usually characterized by the presence of hyperglycemia,… |
![]() |
An Experience That I Will Never Forget...
June 1, 2012 - Events , Professional Advice / Opinions By: Nancy Simon, Pharm.D. Candidate c/o 2016 – Exploring cities while getting lost, viewing beautiful sights, and eating delicious food: all highlights of my study abroad experience. This past semester was more than I ever expected; I do not even know where to begin. I participated in the Discover the World program through St. John’s… |
![]() |
Dr. Oz and Raspberry Ketones...
June 1, 2012 - Clinical , In the News / Politics , Professional Advice / Opinions By: Lila Ahmed, Pharm.D. Candidate c/o 2013 – Whether you wish to admit it or not, all of us have watched or at least heard of the Dr. Oz Show. I am sure that many of us encounter patients in the pharmacy who say, “I saw this on Dr. Oz; where could I find it?”… |
![]() |
Proton Pump Inhibitor Use and Complications...
June 1, 2012 - Clinical By: Lauren Kaveski, Pharm.D. Candidate c/o 2013 – We see proton pump inhibitors (PPIs) used in many medication regimens, but it is unknown whether the majority of patients receive these medications for appropriate durations or indications. For all labeled indications, other than Zollinger-Ellison Syndrome (a rare condition characterized by damaging gastrin hypersecretion and subsequent hydrochloric… |
![]() |
Student Pharmacist Star of the Month: Michelle Pernice...
April 1, 2012 - Professional Advice / Opinions By: Marie Huang – Each month, the Rho Chi Post has the wonderful opportunity to sit down with an inspiring leader among the student pharmacists here at St. John’s University College of Pharmacy and Allied Health Professions – someone who is not afraid to stand apart from the crowd and can be the change he… |
![]() |
Counterfeit Prescription Medications: A Global Threat...
April 1, 2012 - Featured , In the News / Politics By: Lunbao (Jerry) Huang, Pharm.D. Candidate c/o 2013 – Counterfeit prescription medications are becoming a great concern for us. They have increased worldwide costs and endangered our public safety. Activities related to counterfeit drugs cost our healthcare system an estimated $75 billion in 2010. Many patients were seriously injured and died due to counterfeit medications.… |
![]() |
Faculty Spotlight: Dr. Hira Shafeeq...
April 1, 2012 - Featured , Professional Advice / Opinions By: Jessica Lee, Pharm.D. Candidate c/o 2013 – Dr. Hira Shafeeq received her PharmD in 2009 from St. John’s University. After graduating, she went on to do her PGY-1 at the Brooklyn Hospital Center. Upon finishing her first year of residency, she decided to complete her specialty residency in critical care at University of Chicago… |
![]() |
Jentadueto Approved by FDA for Type 2 Diabetes Mellitus...
March 1, 2012 - Clinical , In the News / Politics By: Ebey P. Soman – The FDA recently approved a combination tablet of linagliptin with metformin hydrochloride (Jentadueto®) for the treatment of type 2 diabetes. Developed by Boehringer Ingelheim and Eli Lilly, the new combination tablet provides a twice-daily treatment option for healthcare providers looking for greater flexibility in treating diabetes. Prescribers may add a… |
![]() |
Faculty Spotlight: Dr. Tran...
March 1, 2012 - Featured , Professional Advice / Opinions By: Shannon Tellier – Dr. Tran is an assistant clinical professor at St. John’s University College of Pharmacy and Allied Health Professions, and a clinical pharmacy manager in Internal Medicine at NewYork-Presbyterian: Columbia University Medical Center. She received her BS in Public Health and Doctor of Pharmacy from the University of North Carolina at Chapel… |
![]() |
CHF, a Rare but Serious Presentation of Graves’ disea...
March 1, 2012 - Clinical , Featured By: James Schurr, Pharm.D. Candidate c/o 2014 – Graves’ disease is an autoimmune disorder that results in a state of thyrotoxicosis, or a cause of hyperthyroidism, due to the Immunoglobulin G-mediated agonism of thyroid stimulating hormone (TSH) receptors located on the thyroid. Stimulation of TSH receptors causes an increase in circulating thyroxine (T4) and triiodothyronine… |
![]() |
Proton Pump Inhibitors and the Treatment of Osteoporosi...
February 1, 2012 - Clinical , Featured By: Neal Shah – Osteoporosis is a disease of the bone characterized by decreased bone mineral density (BMD), which reduces the ability of bone to provide adequate structural support. The main cause of this decreased BMD is inadequate calcium intake or absorption. The decreased BMD can cause diffuse lesions throughout the skeletal system and can… |
![]() |
New Oral Direct Thrombin Inhibitors and Factor Xa Antic...
January 1, 2012 - Clinical , Featured , In the News / Politics By: Neal Shah – Anticlotting agents are staples in the prevention and treatment of thrombotic disorders, such as deep vein thrombosis, stroke, pulmonary embolism, myocardial infarction, and atrial fibrillation.1 Intravenous medications, such as unfractionated heparin (UFH), low molecular weight heparin (LMWH), and direct thrombin inhibitors (DTI), are commonly used in, both, inpatient and outpatient settings.… |
![]() |
Placement of Carisoprodol into Schedule IV...
January 1, 2012 - In the News / Politics By Jena Marion, Pharm.D. Candidate c/o 2013 – On December 12, 2011, the Administrator of the Drug Enforcement Agency (DEA) ruled to place carisoprodol (Soma®) into Schedule IV of the Controlled Substances Act (CSA). Carisoprodol has been in use since it was approved for marketing in the U.S. in 1959 with the indication of “relief… |
![]() |
Choosing Clinical Rotations Sites...
January 1, 2012 - Professional Advice / Opinions By: Ruby Lin, Pharm.D. Candidate c/o 2013 – Rotation selection begins around mid-October for fifth year pharmacy students. You may begin to panic about what sites you should choose from the huge selection that St. John’s University offers. Your upperclassmen may try to help you by sharing their rotation experiences. Alas, what do you do… |
![]() |
Drug Shortages: Impacts and Prevention Measures...
December 1, 2011 - Featured , In the News / Politics , Professional Advice / Opinions By: Jimmy Johnson, PharmD Candidate c/o 2012 – Drug shortages have become more and more of an issue in the health care industry. There are over 200 drugs on the Food and Drug Administration’s (FDA) drug shortage list – a number that has tripled in the last five years.1 The largest impact has been on anesthesia… |
![]() |
Pharmacogenetic Applications in Clinical Practice...
November 1, 2011 - Clinical , Featured By: Neal Shah – The focus of pharmacy is rapidly shifting from simple filling and dispensing of prescriptions to preventative medicine and efficient clinical practice. The field of genetics has been incorporated in many defining therapies and will continue to shape how we treat our patients. Examples discussed here are the roles of human leukocyte… |
![]() |
SpongeBob SquarePants… Harmful?...
November 1, 2011 - Clinical , Featured By: Ebey P. Soman – Current research demonstrates a strong correlation between the length of time a child watches television and decreased long-term attention deficiency disorders. A new study by Lillard and Peterson at the Department of Psychology at the University of Virginia suggests that the popular children‘s television show, SpongeBob SquarePants, might be harmful.… |
![]() |
Faculty Spotlight: Dr. Abu Serajuddin...
November 1, 2011 - Featured , Professional Advice / Opinions By: Ebey P. Soman – Dr. Abu Serajuddin is a true inspiration for student pharmacists who wish to enter the pharmaceutical industry setting. He attained his Bachelors of Pharmacy with honors at Dhaka University in Bangladesh and majored in Pharmaceutics to get his Master of Sciences degree at Columbia University in New York. He obtained… |